Xenetic Biosciences (XBIO) Competitors $3.59 -0.04 (-1.10%) Closing price 04:00 PM EasternExtended Trading$3.58 0.00 (-0.14%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsOwnershipSEC FilingsShort InterestTrends XBIO vs. ALLK, DRRX, ANVS, PMN, RNXT, LEXX, ENLV, BIVI, SCNX, and CMMBShould you be buying Xenetic Biosciences stock or one of its competitors? The main competitors of Xenetic Biosciences include Allakos (ALLK), DURECT (DRRX), Annovis Bio (ANVS), ProMIS Neurosciences (PMN), RenovoRx (RNXT), Lexaria Bioscience (LEXX), Enlivex Therapeutics (ENLV), BioVie (BIVI), Scienture (SCNX), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical preparations" industry. Xenetic Biosciences vs. Allakos DURECT Annovis Bio ProMIS Neurosciences RenovoRx Lexaria Bioscience Enlivex Therapeutics BioVie Scienture Chemomab Therapeutics Xenetic Biosciences (NASDAQ:XBIO) and Allakos (NASDAQ:ALLK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, community ranking, analyst recommendations, profitability, dividends, valuation and earnings. Does the MarketBeat Community favor XBIO or ALLK? Allakos received 9 more outperform votes than Xenetic Biosciences when rated by MarketBeat users. However, 67.44% of users gave Xenetic Biosciences an outperform vote while only 58.84% of users gave Allakos an outperform vote. CompanyUnderperformOutperformXenetic BiosciencesOutperform Votes17467.44% Underperform Votes8432.56% AllakosOutperform Votes18358.84% Underperform Votes12841.16% Do analysts recommend XBIO or ALLK? Allakos has a consensus price target of $2.00, indicating a potential upside of 668.94%. Given Allakos' stronger consensus rating and higher probable upside, analysts clearly believe Allakos is more favorable than Xenetic Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenetic Biosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Allakos 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media prefer XBIO or ALLK? In the previous week, Allakos had 1 more articles in the media than Xenetic Biosciences. MarketBeat recorded 4 mentions for Allakos and 3 mentions for Xenetic Biosciences. Xenetic Biosciences' average media sentiment score of 1.28 beat Allakos' score of 0.72 indicating that Xenetic Biosciences is being referred to more favorably in the media. Company Overall Sentiment Xenetic Biosciences Positive Allakos Positive Which has more risk & volatility, XBIO or ALLK? Xenetic Biosciences has a beta of 2.17, meaning that its stock price is 117% more volatile than the S&P 500. Comparatively, Allakos has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Do insiders and institutionals hold more shares of XBIO or ALLK? 15.1% of Xenetic Biosciences shares are held by institutional investors. Comparatively, 84.6% of Allakos shares are held by institutional investors. 14.7% of Xenetic Biosciences shares are held by company insiders. Comparatively, 16.1% of Allakos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is XBIO or ALLK more profitable? Allakos has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -161.63%. Xenetic Biosciences' return on equity of -49.51% beat Allakos' return on equity.Company Net Margins Return on Equity Return on Assets Xenetic Biosciences-161.63% -49.51% -43.99% Allakos N/A -140.87%-86.22% Which has preferable valuation and earnings, XBIO or ALLK? Xenetic Biosciences has higher revenue and earnings than Allakos. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Allakos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXenetic Biosciences$2.52M2.19-$4.14M-$2.66-1.35AllakosN/AN/A-$185.70M-$2.03-0.13 SummaryAllakos beats Xenetic Biosciences on 10 of the 17 factors compared between the two stocks. Remove Ads Get Xenetic Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XBIO vs. The Competition Export to ExcelMetricXenetic BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.54M$6.93B$5.64B$8.08BDividend YieldN/A2.71%4.89%4.04%P/E Ratio-1.356.1223.7319.00Price / Sales2.19226.08381.75120.61Price / CashN/A65.6738.0534.64Price / Book0.566.656.904.26Net Income-$4.14M$139.34M$3.18B$247.00M7 Day Performance-6.27%-0.67%6.23%-2.60%1 Month Performance-14.52%-5.95%1.18%-8.62%1 Year Performance-10.25%-5.21%12.45%2.07% Xenetic Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XBIOXenetic Biosciences1.1537 of 5 stars$3.59-1.1%N/A-12.6%$5.54M$2.52M-1.354Short Interest ↑Positive NewsALLKAllakos4.6025 of 5 stars$0.27-3.5%$2.00+640.7%-82.3%$24.12MN/A-0.13190Upcoming EarningsShort Interest ↓News CoverageDRRXDURECT3.7093 of 5 stars$0.76-4.9%$5.00+558.8%-19.0%$23.56M$8.59M-1.2480Analyst ForecastNews CoverageGap UpANVSAnnovis Bio1.7775 of 5 stars$1.65-9.8%$37.00+2,142.4%-82.4%$23.49MN/A-0.373Short Interest ↑Positive NewsGap UpPMNProMIS Neurosciences0.9873 of 5 stars$0.70-1.4%N/A-61.4%$22.88MN/A-7.005Short Interest ↓News CoverageRNXTRenovoRx1.8193 of 5 stars$0.95-5.0%$9.00+847.4%-44.6%$22.80MN/A-1.676LEXXLexaria Bioscience2.6736 of 5 stars$1.28-12.9%$9.50+642.2%-77.3%$22.47M$496,923.00-2.567ENLVEnlivex Therapeutics2.7864 of 5 stars$1.02-15.0%$9.50+831.4%-68.6%$21.83MN/A-1.0470Gap DownHigh Trading VolumeBIVIBioVie2.2472 of 5 stars$1.18-11.3%$3.00+154.2%+50.4%$21.77MN/A-0.1210Gap UpSCNXScientureN/A$2.48-6.4%N/AN/A$21.70M$7.12M0.00N/AGap DownCMMBChemomab Therapeutics2.9567 of 5 stars$1.51-10.1%$9.00+496.0%+64.9%$21.68MN/A-1.5120Short Interest ↑Gap Down Remove Ads Related Companies and Tools Related Companies ALLK Competitors DRRX Competitors ANVS Competitors PMN Competitors RNXT Competitors LEXX Competitors ENLV Competitors BIVI Competitors SCNX Competitors CMMB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XBIO) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersDOGE’s Next Move: Not what you thinkDonald Trump, Elon Musk and the Department of Government Efficiency have kept their word. Moving even faste...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Trump Orders ‘National Digital Asset Stockpile’ THIS could be the coin they choose…Crypto 101 Media | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenetic Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
